Dr. Aleksandra Walczak joined Ardigen’s Scientific Board to support the development of AI platforms for the discovery of cell therapies.

September 7, 2021 – Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Dr. Aleksandra Walczak joined the company’s Scientific Council. With a PhD in physical sciences and her knowledge and experience, she will support Ardigen’s work on platforms that use artificial intelligence to accelerate and optimize the discovery of modern cell therapies.

Dr. Aleksandra Walczak is an internationally recognized specialist in the field of computational biology and immunology. She has co-authored over 100 scientific publications, and one of her main research topics is the analysis of the diversity and complexity of receptors on the surface of B and T cells, which are involved in triggering an immune response.

Dr. Walczak is currently a research director at the National Center for Scientific Research (Center National de la Recherche Scientifique, CNRS) in France.

“Dr. Aleksandra Walczak has a long track record of advancing the science at the intersection of advanced statistical modeling with molecular biology of T-cell receptor repertoire. We are happy to receive her advice on the matters at the very core of our technology platforms”  – said Agnieszka Blum, General Director of Immunology at Ardigen.

About Ardigen:

Ardigen is harnessing advanced AI methods for novel precision medicine. The company accelerates therapy development by designing immunity, decoding microbiomes, analyzing biomedical images and providing digital drug discovery services. Ardigen’s team is rooted in biology and has extensive expertise in bioinformatics, machine learning, and software engineering. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective precision therapies.

More information at ardigen.com